Biotech Daily

Thursday July 16, 2026

Daily news on ASX-listed biotechnology companies

*** ASX FLAT, BIOTECH DOWN: AVITA UP 16%; CYCLOPHARM DOWN 6%**

*** ADVANCELL RAISES $450m FOR CANCER THERAPIES**

*** 4D MEDICAL: US CONGRESS $29m BILL FOR VETERANS LUNG IMAGING**

*** MICROBA RECEIPTS DOWN 11% TO $16m**

*** IMMURON TRAVELAN SALES UP 6% TO $8m**

*** SALUDA 1st US EVOKE CAP24 SURGERIES**

*** TELIX OPENS NORTH MELBOURNE FACTORY, RESEARCH SITE**

*** CHIMERIC: 'ENCOURAGING CDH17 ANTI-TUMOR ACTIVITY'**

*** ARGENICA 'ARG-007 SIGNIFICANTLY REDUCES BRAIN INJURY, IN RATS'**

*** TELIX, ST VINCENT'S 1st PHASE II TLX597-Tx PROSTATE CANCER PATIENT**

*** EPIMINDER ENROLS 50 US EPILEPSY MONITOR PATIENTS**

*** TRIVARX STABL-IM FOR PHASE I TUMOR IMAGING TRIAL**

*** NYRADA PLEADS 'SCHULTZ' TO ASX 30.5% PRICE QUERY**

*** PYC EGM 13% OPPOSE M-D DR ROHAN HOCKINGS OPTIONS**

*** ENLITIC 683m DIRECTOR OPTIONS, 1-FOR-10 CONSOLIDATION EGM**

*** EBR: BRANDON, CARNEGIE, HESTA, HOST PLUS, REGAL, SPLIT ROCK SUBSTANTIALS**

*** CLARITY APPOINTS ALLISON ROSSITER DIRECTOR**

*** MARK AZZI TAKES 9% OF NYRADA**

MARKET REPORT

The Australian stock market slipped less than 0.01 percent on Thursday July 16, 2026, with the ASX200 down 0.4 points to 8,840.7 points. Thirteen of the Biotech Daily Top 40 companies were up, 17 fell, nine traded unchanged and one was untraded.

Avita was the best, up 18.5 cents or 16.1 percent to $1.335, with 941,615 shares traded. Paradigm climbed 9.4 percent; Amplia and Mesoblast rose seven percent or more; both Nova Eye and Syntara improved 4.55 percent; Atomo and Polynovo climbed three percent or more; Micro-X and Resmed rose more than two percent; Alcidion, Clinuvel and Nanosonics were up one percent or more; with CSL, Imricor and Pro Medicus up by less than one percent.

Cyclopharm led the falls, down 3.5 cents or 5.7 percent to 57.5 cents, with 88,054 shares traded. Artrya, Curvebeam and Immutep lost more than five percent; Actinogen, Prescient and Resonance fell four percent or more; Emvision was down 3.7 percent; 4D Medical, Proteomics, Orthocell and Telix shed two percent or more; Imugene and Lumos lost one percent or more; with Cochlear, Neuren, Racura and Saluda down less than one percent.

ADVANCELL PTY LTD

Advancell says it has raised $US315 million ($A450 million) in an 'oversubscribed' series D funding round for its cancer therapies and to expand manufacturing infrastructure.
Advancell said the financing was co-led by New York healthcare investment firm Ally Bridge Group and the Miami, Florida-based asset management fund Alpha Wave, with participation from Bain Capital Life Sciences, Fidelity Management, T Rowe Price, Eventide Asset Management and Velosity Capital, as well as existing investors, including Brandon Capital, Symbiosis, Tenmile, Proto Axiom and Time Bioventures.
The company said the funds would be used for its ADVC001 lead-212 prostate specific membrane antigen (PSMA)-targeted radio-ligand therapy for metastatic prostate cancer phase III trial, to expand its radio-pharmaceutical platform and manufacturing infrastructure and develop its pipeline of targeted alpha therapies.
Advancell said that Ally Bridge Group managing-director Andrew Lam and Alpha Wave life sciences director Nik Economopoulos were appointed as directors.
Advancell chief executive officer Dr Philina Lee said the funding was "a transformational milestone for Advancell and reflects the conviction of an exceptional investor syndicate in the potential of ADVC001 and the innovation behind our … lead-212 platform".
"This financing puts us in a strong position to enter our next stage of growth and execution, advancing our lead therapy ADVC001 toward registrational development, expanding isotope supply and manufacturing infrastructure to support phase III and future commercial demand, and progressing our lead-212 pipeline into the clinic," Dr Lee said.
"These priorities establish a clear path towards a diversified clinical pipeline with the goal of bringing the promise of targeted alpha therapy to more patients with cancer," she said.
Advancell is a private company.

4D MEDICAL

4D Medical says, if passed, a US Congress Bill will authorize $US20 million ($A29 million) for a Veterans Affairs pilot program of its lung imaging products.
4D Medical said the bi-partisan Bill, the 'Air Care for Vets Act', had been introduced into the US House of Representatives and would direct the US Department of Veterans Affairs to open a pilot program using its regulatory approved functional lung imaging to identify respiratory disorders and lung disease in veterans.
The company said the Bill was introduced by Republican Juan Ciscomani and Democrat Chris Pappas and the House Committee on Veterans' Affairs would consider the legislation and determine whether it should progress through the legislative process.
4D Medical said the Bill defined an eligible product as a 4-dimensional functional lung imaging software product with US Food and Drug Administration authorization to evaluate lung function, and that its XV LVAS imaging product sat "squarely within that definition".
In 2023, the company said the US Centres for Medicare and Medicaid Services (CMS) would reimburse $US299 ($A456) for its XV lung ventilation analysis software (LVAS) scans for lung disease (BD: Nov 13, 2023).
Today, 4D Medical managing-director Prof Andreas Fouras said the pilot program was "a landmark step toward improving how respiratory disease is identified, assessed and managed across the US veteran's healthcare system".
"Those who have served carry a disproportionate burden of respiratory disease, and too much of it is missed by the tests in use today," Prof Fouras said. "I commend Representatives Ciscomani and Pappas for this leadership, and welcome the focus the House Committee on Veterans' Affairs brings to the health of veterans".
4D Medical fell 11 cents or 2.8 percent to $3.79 with 11.2 million shares traded.

MICROBA LIFE SCIENCES

Microba says receipts from customers for the year to June 30, 2026 were down 11.1 percent to $15,752,000, compared to the previous corresponding period.
Microba said receipts for the three months to June 30, 2026 from sales of its Metapanel and Microbiome Explorer gastro-intestinal disorder test kits, supplements and Invivo-branded products fell 1.15 percent to $3,950,000, compared to the prior period.
The company said the reduced revenue reflected the phase out of “discontinued legacy product revenues and a focus on Microba’s core testing, and Invivo supplement products”.
Microba said streamlining operations to a lower cost base was “well progressed, with targeted total annual cash costs expected to reduce by over $7 million per year once fully implemented, with full benefit expected to be realized [by 2027]”.
The company said it had a $3,430,000 three month cash burn, with cash and equivalents of $7,949,000 at June 30, 2026 compared to $11,742,000 at June 30, 2025, leaving it with 2.3 quarters of cash; as well as a $2,050,000 R&DTI loan from Radium Capital and a $629,000 loan from Westpac at 7.39 percent annual interest.
Microba was up 0.1 cents or 2.4 percent to 4.2 cents.

IMMURON

Immuron says sales of its Travelan for traveler’s diarrhoea for the year to June 30, 2026 were up 5.5 percent to $7.7 million, compared to the prior corresponding period.
Last year, Immuron said unaudited sales for the year to June 30, 2025 of its hyperimmune products including Travelan for traveler’s diarrhoea targeting pathogenic bacteria and toxins in the gastrointestinal tract were up 48.9 percent to $7.3 million (BD: Jul 17, 2025).
Today, the company said Australian sales rose 10 percent to $5,800,000, with US sales up seven percent to $1,800,000 and Canadian sales down 55 percent to $200,000.
Immuron said sales rose in Australia due to increased awareness and travel, with US sales up due to a “marketing initiatives” and it was building Canadian awareness.
Immuron was unchanged at 4.3 cents with one share traded.

SALUDA MEDICAL

Saluda says the first US surgical cases using its Evoke CAP24 paddle lead for spinal cord stimulation have been completed following US Food and Drug Administration approval.
Last year, Saluda raised $231 million in an initial public offer for its FDA-approved Evoke spinal cord simulation for pain relief; and last month, said it had FDA approval allowing it to market and sell its CAP24 paddle lead (BD: Dec 5, 2025; Jun 30, 2026).
Today, the company said the first procedures using its paddle lead were at Fayetteville’s University of Arkansas for Medical Sciences on July 10, and later at Pennsylvania’s Advanced Surgery Center of Lancaster on July 14, 2026.
Saluda said the surgeries were the “first time Evoke physiologic closed-loop therapy has been delivered in surgical paddle lead procedures in the US”.
The company said paddle leads were “preferred by many neurosurgeons and orthopaedic spine surgeons and represent roughly 30 percent of US [spinal cord stimulation] implants, opening an important new segment for Evoke Therapy”.
Saluda said CAP24 was the first spinal cord stimulation paddle lead “engineered specifically for closed-loop neuro-modulation, designed to sense each patient’s neural signals and support precise, objective therapy”.
Saluda chief commercial officer Mike Mathias said the cases were an important milestone.
Saluda fell half a cent or 0.9 percent to 53 cents.

TELIX PHARMACEUTICALS

Telix says it has opened its “multi-million dollar” radio-pharmaceutical research, manufacturing and treatment facility in North Melbourne.

In an announcement not released to the ASX, Telix said the facility “combined radio-chemistry laboratories, clinical product manufacturing, patient dose administration and imaging at a single site, in a first for Australia”.

The company said that “the facility would address manufacturing capacity constraints and the need to make and administer radio-pharmaceutical doses close to patients and was intended to significantly reduce the time from early-stage trials to broad patient access”.

Telix said patient care and research would be delivered by the Melbourne Theranostic, or combined diagnostics and therapeutics, Innovation Centre, covering Telix-sponsored studies, investigator-initiated trials and third-party collaborations.

The company did not disclose the cost of the facility.

Telix managing-director Dr Christian Behrenbruch said that the facility would allow the company “to move new treatments from research into the clinic and patient use more efficiently”.

“It is also an investment in Australia's sovereign manufacturing capability and the specialist workforce needed to build a globally competitive radio-pharmaceutical industry,” Dr Behrenbruch said.

Melbourne Theranostic Innovation Centre founder and chief medical officer Prof Rod Hicks said the facility would "give clinicians faster access to novel radiopharmaceuticals and allow emerging technologies to be assessed in a real-world clinical setting".

Telix fell 42 cents or 2.6 percent to $15.61 with 1.1 million shares traded.

CHIMERIC THERAPEUTICS

Chimeric says two of four phase I/II gastro-intestinal cancer patients dosed with 450,000,000 CHM CDH17 cells show “encouraging signs of anti-tumor activity”.

Last year, Chimeric said it enrolled the first of 15 patients in its phase I/II trial of CDH17 chimeric antigen receptor (CAR) T-cell therapy, or CHM2101, for colorectal and gastric cancer and intestinal neuro-endocrine tumors (BD: Jul 22, 2024).

Earlier this year, the company said nine of 11 evaluable patients (81.8%) had stable disease in the phase I/II trial of CHM CDH17 (BD: Jun 1, 2026).

Today, Chimeric said each patient received a scan at 28 days following treatment and then at 90 days following treatment and that early and preliminary results from two of the four patients treated with dose level three showed “encouraging signs of anti-tumor activity, with the safety profile being monitored for any new toxicities or safety signals”.

The company said the data two patients showed “tumor shrinkage ranging from 17 percent to 40 percent in individual lesions”.

Chimeric said one patient had “stable disease for six months, and another for four months” as assessed by the response evaluation criteria in solid tumors (Recist) 1.1 criteria.

According to the Recist 1.1 criteria, stable disease was “neither sufficient shrinkage to qualify for [partial response] nor sufficient increase to qualify for [progressive disease], taking as reference the smallest sum diameters while on study”.

The company said “no additional safety signals have arisen to date”.

Chimeric said it had completed manufacturing for the fifth patient at dose level three, “with dosing expected in the coming weeks” and the sixth and final patient in the study would be “dosed by the end of 2026, subject to funding”.

Chimeric fell 0.3 cents or 5.9 percent to 4.8 cents.

ARGENICA THERAPEUTICS

Argenica says ARG-007, or xaranetide, shows “significant efficacy in reducing the secondary injury effects in repeated mild traumatic brain injury, or concussion” in rats.
Argenica said the study by Perth’s Curtin University showed ARG-007 had “broad neuro-protective activity by attenuating multiple pathological processes implicated in concussion, including neuro-inflammation, oxidative stress, and axonal injury”.
The company said the study assessed an intra-venously dosed, one milligram per kilogram ARG-007 administered 30 minutes after repeated mild traumatic brain injury, showing the drug “significantly reduced neuro-inflammation, oxidative stress and axonal damage, three of the most significant components of the secondary injury cascade seen following concussion”.
Argenica said the ARG-007 effect was enduring, lasting up-to 11 days post-injury.
The company said the study suggested “the therapy may not simply alleviate symptoms but may modify the underlying biological response to concussion”.
Argenica said the findings were “consistent with previously reported efficacy in multiple moderate and severe traumatic brain injury models, demonstrating biological activity across the spectrum of traumatic brain injury severity, increasing confidence that xaranetide is targeting fundamental pathways of brain injury”.
Argenica managing-director Dr Liz Dallimore said the findings showed “that a single dose of xaranetide, given soon after repeated mild brain injury, reduced inflammation, oxidative stress, and cellular damage across multiple regions of the brain, processes believed to drive prolonged concussion symptoms and delayed recovery”.
“This is another independent demonstration of xaranetide's efficacy in [traumatic brain injury], adding to a growing body of evidence across mild, moderate, and severe injury models, and reinforcing its potential as a disease-modifying therapy for repeated concussion,” Dr Dallimore said.
“Based on these results, Argenica is now considering next steps to advance xaranetide's development in this indication,” Dr Dallimore said.
Argenica was unchanged at 14 cents with 2.25 million shares traded.

TELIX PHARMACEUTICALS

Telix says with St Vincent’s Hospital it has dosed the first of 20 patients with TLX597-Tx in a phase II, ‘Optimal-e’ trial for metastatic hormone-sensitive prostate cancer.
In an announcement not released to the ASX, Telix said the single-arm, open-label trial would assess TLX597-Tx treatment with androgen deprivation therapy and an androgen receptor pathway inhibitor in men with metastatic hormone-sensitive prostate cancer.
The company said the study would evaluate the impact of TLX597-Tx on prostate specific antigen (PSA) response rate in an earlier treatment setting, assessing its potential to improve both the depth and durability of PSA response, while further evaluating the safety of dose intensification.
Telix said TLX597-Tx had “not received marketing authorization in any jurisdiction”.
Telix chief medical officer Dr David Cade said the beginning of the ‘Optimal-e’ trial was “an important evolution of PSMA-targeted radio-ligand therapy for earlier metastatic prostate cancer, where maintaining quality-of-life is paramount”.
“While the currently approved radio-ligand therapy has demonstrated a modest improvement in overall survival in advanced-stage disease, we believe earlier intervention may offer the potential to further improve outcomes and prolong quality of life for patients,” Dr Cade said.

EPIMINDER

Epiminder says it has enrolled 50 of 210 patients in its prospective, randomized, controlled US study of its Minder epilepsy monitor, with full enrolment by July 2027.
Last year, Epiminder listed on the ASX following a $125 million initial public offer at $1.50 a share to commercialize its implantable epilepsy monitor (BD: Dec 1, 2025).
Earlier this year, the company said the first of 210 drug-resistant epilepsy patients were implanted in a six-month trial of its Minder epilepsy monitor (BD: Jan 19, 2026).
Today, Epiminder managing-director Dr Rohan Hoare said enrolling 50 patients was “a significant milestone and a clear signal of the momentum we have built”.
“With 20 leading epilepsy centres now actively enrolling, we are seeing genuine, demonstrated adoption of the Minder system in a clinical setting,” Dr Hoare said.
“We remain on track to enrol 210 patients by … [July 2027], and we are confident in the foundation we have built to get there,” Dr Hoare said.
Epiminder was up one cent or 2.9 percent to 35.5 cents.

TRIVARX (FORMERLY MEDIBIO)

Trivarx says it has manufactured Stabl-Im for use in its planned phase I clinical feasibility trial for magnetic resonance imaging (MRI) tumors, expected to begin in 2026.
Last year, Trivarx said it would acquire the brain imaging technology from Dr Daniel Tillett-founded Nucleics Pty Ltd (BD: Oct 16, 2025).
Previously, the company said it was developing its MEB-001 and single-lead electrocardiography (EEG) sleep scoring algorithms for major depressive episode.
Earlier this year, Trivarx said that it had appointed Beyond Drug Development as its contract research organization to plan the phase I trial (BD: May 22, 2026).
Today, the company said it was “focused on finalizing the trial design, selecting clinical sites and completing the regulatory, ethics and operational activities required”.
Trivarx was unchanged at two cents.

NYRADA

Nyrada has told the ASX that it is not aware of any information it has not announced which, if known, could explain the recent trading in its securities.
The ASX said that Nyrada’s share price rose 30.5 percent from a low of 41 cents to a high of 53.5 cents yesterday and noted a “significant increase” in the number of shares traded.
Nyrada fell 7.5 cents or 13 percent to 50 cents.

PYC THERAPEUTICS

PYC says its extraordinary general meeting has passed all three resolutions, with up-to 13.04 percent against the issue of options to managing-director Dr Rohan Hockings.
Last month, PYC said investors would vote to increase the director fee pool by 233.3 percent to $1,000,000 and issue $6,760,000 in options to Dr Hockings (BD: Jun 15, 2026).
Today, the company said Dr Hockings’ options were opposed by 54,978,128 votes (13.04%) with 366,564,931 votes (86.96%) in favor; with the rights plan and increase in the director fee pool passed by more than 93.80 percent of the meeting.
According to its most recent notice, PYC had 983,510,447 shares on issue, meaning that Dr Hockings’ options were opposed by 5.6 percent of the company, sufficient to requisition extraordinary general meetings.
PYC was up 5.5 cents or 3.4 percent to $1.67 with 1.6 million shares traded.

ENLITIC

Enlitic says its extraordinary general meeting will vote to issue 683,500,000 options to directors and approve a one-for-10 common stock consolidation.
Enlitic said investors would vote to issue managing-director Michael Sistenich 470,000,000 options, chair Lawrence Gozlan 128,000,000 options and directors Lisa Pettigrew and Sergio Duchini 42,750,000 options, each.
The company said the options would be exercisable at the higher of a 25 percent premium to the closing Chess depository interest (CDI) price at July 28, 2026 and 0.6 cents.
Enlitic said the options were “a cost-effective way for the company to remunerate and incentivize Mr Sistenich as opposed to additional cash remuneration” and were in addition to his $US300,000 ($A428,852) yearly pay, not including superannuation.
The company said Mr Gozlan was paid $US100,000 annually, with Ms Pettigrew and Mr Duchini receiving director fees of $US60,000 per year.
Enlitic said the meeting would vote on a one-for-10 consolidation, which would “not change the total number of authorized shares of the common stock”.
The company said shareholders would vote to increase the authorized stock available for issuance from 2,500,000,000 common stock to 12,000,000,000 common stock.
Enlitic said the meeting would vote to issue awards under the 2023 equity incentive plan, issue CDIs under its placement and share plan, and issue stock for a convertible note.
The meeting will be held online on July 29, 2026 at 10am (AEST).
Enlitic was unchanged at 0.7 cents.

EBR SYSTEMS

EBR says that following its $150 million raise, substantial holders Regal, Hesta, Host Plus, Brandon Capital, MH Carnegie and Split Rock have had changes in ownership.
In June, EBR said it raised $150 million at 38 cents a share (BD: Jun 4, 5, 25, 2026).
Today, EBR said that Regal Funds became substantial with 87,510,124 CDIs (11.62%), Hesta (Health Employees Superannuation Trust Australia) held 37,246,781 CDIs (4.95%), Host Plus (originally Hospitality Superannuation Trust) held 76,259,609 CDIs (10.12%), BCP3 (Brandon Capital Partners) held 20,923,134 CDIs (2.78%), MH Carnegie held 41,485,894 CDIs (5.51%) and Split Rock held 26,728,940 CDIs (3.55%).
The company said that Medical Research Commercialisation Fund 3 (MRCF3) managed funds on behalf of Hesta, Host Plus and Brandon Capital.
EBR was unchanged at 37.5 cents with one million shares traded.

CLARITY PHARMACEUTICALS

Clarity says it has appointed former Genetic Signatures chief executive officer Allison Rossiter as a non-executive director.
Clarity said Ms Rossiter had more than 25 years of experience in diagnostics, pharmaceuticals and medical technology and had been managing-director of Roche Diagnostics Australia and had worked for Pfizer UK and “an ASX-listed diagnostics company” as well as most recently being head of Novartis Australia and New Zealand.
The company said Ms Rossiter held a Bachelor of Science from England’s University of Plymouth.
Last year, Genetic Signatures said Ms Rossiter, who was appointed chief executive officer in 2024, would leave in February 2026 “to take on a role with a global pharmaceutical company” (BD: Jun 4, 2024; Dec 15, 2025).
Clarity was unchanged at $2.45 with three million shares traded.

NYRADA

Nyrada says Mark Azzi has increased his substantial shareholding from 20,229,116 Chess depository interests (CDIs) (8.27%) to 22,933,865 CDIs (9.28%).

Nyrada did not disclose the cost of the additional shares in Mr Azzi's holding.